FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person Fortress Biotech, Inc.				<u>Ch</u>	2. Issuer Name and Ticker or Trading Symbol Checkpoint Therapeutics, Inc. [CKPT]									ationship of F k all applicab Director		Person		vner	
(Last)	(First) (Middle)					3. Date of Earliest Transaction (Month/Day/Year) 01/05/2023								Officer (g below)	ive title		Other (s below)	specify	
1111 KANE CONCOURSE SUITE 301				4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Ind	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street) BAY HARBO ISLANDS	OR _{FL}	3	3154											X		•	•	ng Person Ine Reportin	g Person
(City)	(State	(2	Zip)																
		Т	able I - No	n-Der	ivativ	ve S	ecurit	ies Ac	quired, I	Disp	osed	of, or	Benefi	cially O	vned				
Date		2. Trans Date (Month/	Saction 2A. Deemed Execution Do if any (Month/Day/		on Date,	Code (Inst						Securities Beneficiall Following	5. Amount of Securities Beneficially Owned Following Reported Transaction(s)		nership : Direct (D) lirect (I) . 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
								Code	v	Amount	t (A) or (D)		Price	(Instr. 3 and 4)				(111501.4)	
COMMON ST	ГОСК, РАІ	R VALUE \$0.00	01	01/0	5/2023		A		368,90	007 ⁽¹⁾⁽²⁾ A		\$0.00	1,503,713(2)(3)			D			
			Table II -						ired, Dis						ed				
1. Title of Derivative Security (Instr. 3)	Title of 2. 3. Transaction Pate Execution Date, or Exercise (Month/Day/Year) if any			ansact	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount Securities Underlyin Derivative Security (and 4)				rlying	ng Derivative		er of e s ally	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Co	ode	Date Expiration Number							Amount or Number of Shares		Transact (Instr. 4)	ion(s)			
Class A Common Stock, par value \$0.0001	(4)								(4)		(4)	Comi		700,000 ⁽²⁾		700,00	00	D	

Explanation of Responses:

- 1. The Reporting Person is entitled to an annual equity fee grant from the issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the 2022 annual equity fee grant.
- 2. Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected on this Form 4 has been adjusted to reflect the Reverse Stock Split.
- 3. The total number of shares beneficially owned by the Reporting Person includes those transactions as disclosed on the table filed herewith as Exhibit 99.
- 4. Each share of the Issuer's Class A Preferred Stock is convertible at any time at the option of the Reporting Person into one share of the Issuer's Common Stock and has no expiration date.

/s/ Samuel Berry, General Counsel and Authorized Agent 01/06/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

 $Note: File \ three \ copies \ of \ this \ Form, \ one \ of \ which \ must \ be \ manually \ signed. \ If \ space \ is \ insufficient, \ see \ Instruction \ 6 \ for \ procedure.$

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	3. Transaction (Instr. 8)	Code	4. Securiti or Dispose (Instr. 3, 4	ed Of (D)	ed (A)	Securities	6. Ownership Form: Direct (D) or Indirect (I	of Indirect Beneficial
		Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4) (3)	(Instr. 4)	
COMMON STOCK, PAR VALUE \$0.0001	1/1/2018	A		59,183 ⁽¹⁾	A	\$0.00	329,454	D	
COMMON STOCK, PAR VALUE \$0.0001	3/12/2018	A		13,225 ⁽²⁾	A	\$0.00	342,679	D	
COMMON STOCK, PAR VALUE \$0.0001	9/26/2018	A		4,604 ⁽²⁾	A	\$0.00	347,283	D	
COMMON STOCK, PAR VALUE \$0.0001	1/1/2019	A		96,043 ⁽¹⁾	A	\$0.00	443,326	D	
COMMON STOCK, PAR VALUE \$0.0001	2/14/2019	A		225 ⁽²⁾	A	\$0.00	443,551	D	
COMMON STOCK, PAR VALUE \$0.0001	6/28/2019	A		2,494 ⁽²⁾	A	\$0.00	446,045	D	
COMMON STOCK, PAR VALUE \$0.0001	9/24/2019	A		2,834 ⁽²⁾	A	\$0.00	448,879	D	
COMMON STOCK, PAR VALUE \$0.0001	9/30/2019	A		22 ⁽²⁾	A	\$0.00	448,901	D	
COMMON STOCK, PAR VALUE \$0.0001	11/27/2019	A		38,500 ⁽²⁾	A	\$0.00	487,401	D	
COMMON STOCK, PAR VALUE \$0.0001	11/27/2019	A		106 ⁽²⁾	A	\$0.00	487,507	D	
COMMON STOCK, PAR VALUE \$0.0001	2/6/2020	J		2,500 ⁽⁴⁾	D	\$0.00	485,007	D	
COMMON STOCK, PAR VALUE \$0.0001	6/4/2020	A		145,931 ⁽¹⁾	A	\$0.00	630,938	D	
COMMON STOCK, PAR VALUE \$0.0001	6/30/2020	A		3,257 ⁽²⁾	A	\$0.00	634,195	D	
COMMON STOCK, PAR VALUE \$0.0001	9/22/2020	A		5,777 ⁽²⁾	A	\$0.00	639,972	D	
COMMON STOCK, PAR VALUE \$0.0001	9/22/2020	A		18,304 ⁽²⁾	A	\$0.00	658,276	D	
COMMON STOCK, PAR VALUE \$0.0001	12/30/2020	A		3,724 ⁽²⁾	A	\$0.00	662,000	D	
COMMON STOCK, PAR VALUE \$0.0001	1/1/2021	A		174,245 ⁽¹⁾	A	\$0.00	836,245	D	

1. Title of Security (Instr. 3)	Date Exect (Month/Day/Year)if any		2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Cod			es Acquire ed Of (D) and 5) ⁽³⁾	. ,	Securities	Direct (D)	of Indirect Beneficial
		Cod		V	Amount	(A) or (D)	Price	Reported	(Instr. 4)	(Instr. 4)
COMMON STOCK, PAR VALUE \$0.0001	3/29/2021		A		17,563 ⁽¹⁾	A	\$0.00	853,808	D	
COMMON STOCK, PAR VALUE \$0.0001	6/29/2021		A		8,436 ⁽²⁾	A	\$0.00	862,244	D	
COMMON STOCK, PAR VALUE \$0.0001	9/29/2021		A		1,153 ⁽²⁾	A	\$0.00	863,397	D	
COMMON STOCK, PAR VALUE \$0.0001	11/30/2021		A		2,597 ⁽²⁾	A	\$0.00	865,994	D	
COMMON STOCK, PAR VALUE \$0.0001	1/1/2022		A		212,142 ⁽¹⁾	A	\$0.00	1,078,136	D	

COMMON STOCK, PAR VALUE \$0.0001	3/31/2022	A	9,355 ⁽²⁾	A	\$0.00	1,087,491	D	
COMMON STOCK, PAR VALUE \$0.0001	4/5/2022	A	220 ⁽²⁾	A	\$0.00	1,087,711	D	
COMMON STOCK, PAR VALUE \$0.0001	6/29/2022	A	1,189 ⁽²⁾	A	\$0.00	1,088,990	D	
COMMON STOCK, PAR VALUE \$0.0001	9/27/2022	A	2,129 ⁽²⁾	A	\$0.00	1,091,029	D	
COMMON STOCK, PAR VALUE \$0.0001	12/6/2022	A	424 ⁽²⁾	A	\$0.00	1,091,453	D	
COMMON STOCK, PAR VALUE \$0.0001	12/16/2022	A	43,353 ⁽²⁾	A	\$0.00	1,134,806	D	

Explanation of Responses:

- 1. The Reporting Person is entitled to an annual equity fee grant from the Issuer of a number of shares of the Issuer's Common Stock equal to 2.5% of the Issuer's fully diluted outstanding capitalization on December 31. These shares were granted by the Issuer to the Reporting Person for the annual equity fee grant.
- 2. The Issuer is required to grant to the Reporting Person an equity fee in shares of the Issuer's Common Stock equal to 2.5% of the gross amount of any debt or equity financing consummated by the Issuer. These shares were granted by the Issuer to the Reporting Person following the closing of a financing.

 3. Effective December 6, 2022, the Issuer effected a one-for-ten reverse stock split of its common stock (the "Reverse Stock Split"). The amount of common stock reflected in
- this Exhibit 99 has been adjusted to reflect the Reverse Stock Split.
- 4. Transfer to employees as service grants in consideration of services provided to the Reporting Person and to Issuer.